Models showed this adjustment successfully eliminated effects of eGFR, BUN, and diabetes on plasma levels, with no compromise to model estimates of known AD-related factors (effect sizes for ADD and APOE ε4 were modestly/non-significantly increased). The gene discussed is APOE; the disease is diabetes mellitus.